Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens.
Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M, Prentice HG, Garg M, Yin JA, Byrne J, Russell NH, Mufti GJ. Parker JE, et al. Among authors: russell nh. Br J Haematol. 2002 Oct;119(1):144-54. doi: 10.1046/j.1365-2141.2002.03796.x. Br J Haematol. 2002. PMID: 12358919 Free article.
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, Taghipour G, Schmitz N; Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Robinson SP, et al. Blood. 2002 Dec 15;100(13):4310-6. doi: 10.1182/blood-2001-11-0107. Epub 2002 Aug 15. Blood. 2002. PMID: 12393626 Free article.
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.
Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG, Potter M, Pagliuca A, Ho A, Devereux S, McQuaker G, Mufti G, Yin JL, Russell NH. Faulkner RD, et al. Among authors: russell nh. Blood. 2004 Jan 15;103(2):428-34. doi: 10.1182/blood-2003-05-1406. Epub 2003 Sep 11. Blood. 2004. PMID: 12969983 Free article.
Chromosomal abnormalities in Ph- cells of patients on imatinib.
McMullin MF, Humphreys M, Byrne J, Russell NH, Cuthbert RJ, O'Dwyer ME. McMullin MF, et al. Among authors: russell nh. Blood. 2003 Oct 1;102(7):2700-1; author reply 2701. doi: 10.1182/blood-2003-06-1943. Blood. 2003. PMID: 14504073 Free article. No abstract available.
The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma.
Shaw BE, Peggs K, Bird JM, Cavenagh J, Hunter A, Alejandro Madrigal J, Russell NH, Sirohi B, Towlson K, Williams CD, Marks DI; Clinical Trials Committee of the British Society of Blood and Marrow Transplantation. Shaw BE, et al. Among authors: russell nh. Br J Haematol. 2003 Dec;123(5):886-95. doi: 10.1046/j.1365-2141.2003.04714.x. Br J Haematol. 2003. PMID: 14632780 Free article.
302 results